Kan S et al. |
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. |
2015 |
BMC Cancer |
pmid:26475267
|
Montero JC et al. |
Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. |
2015 |
Oncotarget |
pmid:26336133
|
Krop IE et al. |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. |
2015 |
Ann. Oncol. |
pmid:25355722
|
Yabe N et al. |
[A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)]. |
2015 |
Gan To Kagaku Ryoho |
pmid:26805183
|
Michel LL et al. |
T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. |
2015 |
Anticancer Res. |
pmid:26254411
|
Piwko C et al. |
Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. |
2015 |
Clin Drug Investig |
pmid:26123628
|
Hayashi T et al. |
Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. |
2015 |
J. Urol. |
pmid:26047983
|
Shen BQ et al. |
Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. |
2015 |
Drug Metab Lett |
pmid:26031461
|
Kan S et al. |
Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. |
2015 |
Oncol. Rep. |
pmid:25976081
|
Dholaria B and Srinivasan S |
T-DM1-related carotenoderma and hand-foot syndrome. |
2015 |
Lancet |
pmid:25933279
|
Van den Mooter T et al. |
Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. |
2015 |
Expert Opin Biol Ther |
pmid:25865453
|
Hong EE et al. |
Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. |
2015 |
Mol. Pharm. |
pmid:25856201
|
Widdison W et al. |
Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. |
2015 |
Mol. Pharm. |
pmid:25826705
|
Guerin M et al. |
[Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. |
2015 |
Bull Cancer |
pmid:25790739
|
Nguyen-Ngoc T and Raymond E |
Reinvention of chemotherapy: drug conjugates and nanoparticles. |
2015 |
Curr Opin Oncol |
pmid:25783982
|
Mustacchi G et al. |
HER2-positive metastatic breast cancer: a changing scenario. |
2015 |
Crit. Rev. Oncol. Hematol. |
pmid:25748080
|
Salomon PL and Singh R |
Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells. |
2015 |
Mol. Pharm. |
pmid:25738394
|
Baron JM et al. |
Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. |
2015 |
J Oncol Pharm Pract |
pmid:24682654
|
Singh JC and Lichtman SM |
Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. |
2015 |
Drugs Aging |
pmid:26645293
|
Hamblett KJ et al. |
SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. |
2015 |
Cancer Res. |
pmid:26631267
|